Neogenomics Inc (NEO) Files Form 4 Insider Selling : Steven A Ross Sells 112,500 Shares

Neogenomics Inc (NEO): Steven A Ross , CIO of Neogenomics Inc sold 112,500 shares on Apr 29, 2016. The Insider selling transaction was reported by the company on May 3, 2016 to the Securities and Exchange Commission. The shares were sold at $8.11 per share for a total value of $912,375.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 14, 2016, George Cardoza (Chief Financial Officer) sold 32,000 shares at $6.83 per share price.On Mar 10, 2016, Oort Douglas M Van (Chairman and CEO) sold 450,000 shares at $7.06 per share price.Also, On Mar 7, 2016, Kevin C Johnson (director) purchased 22,007 shares at $6.80 per share price.On Mar 4, 2016, Alison L. Hannah (director) purchased 10,000 shares at $6.90 per share price.

NeoGenomics: On Monday, May 2, 2016 heightened volatility was witnessed in NeoGenomics which led to swings in the share price. The shares opened for trading at $8.23 and hit $8.4 on the upside , eventually ending the session at $8.21, with a gain of 0.86% or 0.07 points. The heightened volatility saw the trading volume jump to 10,94,963 shares. The 52-week high of the share price is $8.48 and the company has a market cap of $623 M . The 52-week low of the share price is at $4.6.

NeoGenomics Money Flow Index Chart

Company has been under the radar of several Street Analysts.NeoGenomics is Reiterated by The Benchmark Company to Buy and the brokerage firm has raised the Price Target to $ 9 from a previous price target of $8 .The Rating was issued on Apr 28, 2016.NeoGenomics is Initiated by The Benchmark Company to Buy and the brokerage firm has set the Price Target at $8. The Rating was issued on Mar 11, 2016.

NeoGenomics Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company offers testing services which includes Cytogenetics testing which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing which is a process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to in biological tissues. and molecular testing which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA) as well as the structure and function of genes at a molecular level.

Leave a Reply

NeoGenomics - Is it time to Sell?

Top Brokerage Firms are advising their investors on NeoGenomics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.